A gloved hand holding an empty orange prescription vial against a pale marble background

How Do I Switch From Compounded Semaglutide or Tirzepatide to Wegovy or Zepbound?

On November 6, 2026November 5, 2026 By Dr. Scott RennieIn Weight Loss & Metabolic HealthLeave a comment

The short answer: you switch by getting a new prescription for Wegovy, Zepbound, or one of the new pills, and your prescriber picks the starting dose. A compounded dose does not convert cleanly to a brand dose, so the number on your old vial is a clue rather than an instruction.

If you have been off for more than a couple of weeks, or nobody can tell you exactly what was in your vial, the safest default is to restart near the bottom of the label schedule and climb. That costs you some weeks. Guessing high can cost you days of vomiting.

Why your compounded supply is drying up

Pharmacies were allowed to copy semaglutide and tirzepatide while the brand products were in shortage. The shortages ended. FDA declared the tirzepatide shortage resolved on October 2, 2024, confirmed that on December 19, 2024, and declared the semaglutide shortage resolved on February 21, 2025. The enforcement grace periods for state-licensed pharmacies and outsourcing facilities then closed in steps through the spring of 2025 (1).

2026 has added pressure from the other direction. FDA’s April 1, 2026 update says plainly that tirzepatide and semaglutide are on neither the 503B bulks list nor the drug shortage list (1). On April 30 the agency proposed excluding semaglutide, tirzepatide, and liraglutide from that bulks list permanently, with a comment period that closed July 30 after an extension (2). And on March 3 it sent warning letters to 30 telehealth companies over marketing that implied their compounded products were the same as approved ones (3). As of early November 2026 there was no final decision on the bulks proposal, so treat that piece as pending.

A narrow lane survives. FDA will not treat a compounded product as essentially a copy when a prescriber determines and documents a change that makes a significant difference for an identified patient (1). It also says a semaglutide plus B12 product can still be judged a copy when both strengths fall within 10 percent of the commercial products (1). If your supplier is shipping less, relabeling, or closing its compounded program, this is the reason. It is a regulatory story and says nothing about you.

I covered the safety checklist and the history in Compounded Semaglutide and Tirzepatide: What to Know Now. This post is the practical follow-up for someone who has to make the move.

Why can’t I just convert my compounded dose?

Because the label on a compounded vial and the label on a pen are written in different languages, and sometimes describe different molecules.

Start with units. Compounded product usually arrives in a multi-dose vial that you draw up with a syringe. A poison control case series in the Journal of the American Pharmacists Association described three patients with adverse events after compounded semaglutide, two of them 10-fold dosing errors, and one who was dosing in milliliters and units instead of milligrams. One needed an antiemetic and intravenous fluids (4). A pen clicks to a fixed dose. A syringe asks you to do arithmetic.

Then the ingredient. FDA states that semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved drugs, and says it knows of no lawful basis for using those salts in compounding. It has also logged reports of patients getting more product per dose, dosing more often, or titrating faster than the label allows (5). As of May 31, 2026, the agency counted 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, and it says underreporting is likely (5).

So a compounded vial labeled “2.5 mg weekly” and a Zepbound 2.5 mg pen share a number. They do not share a guarantee.

Restart low, or match the dose?

No label tells you how to switch from a compounded product, because none of them contemplate it. What the labels do tell us is how to restart after a gap, and that is the closest evidence we have.

The Wegovy label says that if two or more consecutive weekly doses are missed, reinitiate dose escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions (6). The Zepbound label addresses only a single late dose (7), but Lilly’s medical information page describes what the SURMOUNT trials did: after one or two missed doses, treatment restarted at the same dose if it had been well tolerated, and after three or more, it restarted at 5 mg regardless of the prior dose (8). The Foundayo label sets its trigger at seven or more consecutive missed daily doses, again with reinitiation at a lower dosage (9).

Read together, gap length is the first variable. A short gap on a known, well-tolerated dose makes matching defensible. A longer gap pushes you down the schedule. The second variable is certainty. If the pharmacy is unknown, the concentration is unclear, or the patient cannot say how many units they drew, leaning low is the safer choice. My view is that the two errors are not symmetrical. Starting too low delays the result by a few weeks. Starting too high can mean days of vomiting and, rarely, a trip for fluids.

For scale, here is what low looks like. Wegovy starts at 0.25 mg and reaches 1 mg at week 9, with each step lasting four weeks. Zepbound starts at 2.5 mg and reaches 5 mg at week 5 (6,7). The Wegovy label also allows delaying escalation by four weeks if a dose is not tolerated (6).

There is no single number I use. If someone has been getting their medication through a reliable compounding pharmacy, that helps, because there is likely to have been no gap in dosing. If the pharmacy is unknown, or there is some question about how they have felt on the compounded drug, I adjust. Where I start depends on how the patient is doing, which pharmacy and which medication they were using, and whether they have been sick to their stomach or have seen no change in their hunger at all. If they were having side effects on the compounded product, such as nausea bad enough to need a lot of ondansetron, or severe diarrhea or constipation, but they want to try a brand-name medication to see whether that improves, I start them on a lower dose than they were taking. If they have been on a particular compounded dose for a long time and are not losing any weight, I might start higher than the label’s starting dose. It really depends.

What I would gather before the video visit

On a video visit I cannot pick up the vial, so the vial has to come to me as photographs. The useful list is short: the pharmacy label showing drug, concentration, and lot; the syringe type; how many units the patient draws; the date and size of the last injection; the highest dose reached; and every side effect along the way. Patients who bring that make the dose decision easy. Patients who bring “it was the blue one” make it a judgment call.

What I ask for is a photo of the current prescription. It has to show the name of the medication, the dose, the date it was prescribed, and the prescribing doctor. It also has to show any additives, because compounded versions sometimes include them, and I want to see exactly what has been in that vial.

What restarting will feel like

Expect the early weeks of a new start, even if you were on a high dose before. The labels build their escalation schedules specifically to reduce GI side effects (6,7), and tolerance you built on a product of uncertain strength is not a reliable credit. Nausea, early fullness, and constipation are the usual complaints. If a step is rough, hold there rather than push, which the Wegovy label explicitly permits (6).

Some patients feel like they are going backward when the dose drops. They are not. The goal is to land on a dose you can verify, then climb to the effect you want. Persistent vomiting, or an inability to keep fluids down, is a reason to call. My side effects post has the incidence numbers.

What will the brand version cost?

Less than many people expect, though prices move. As I write this, NovoCare lists the Wegovy pen at $199 a month for new patients on the first two fills of the 0.25 mg and 0.5 mg doses, then $349 a month for 0.25 through 2.4 mg, and the Wegovy pill from $149 a month, rising to $299 at the 9 mg and 25 mg strengths. Lilly lists Zepbound self-pay starting at $299 a month for the KwikPen or four vials, and the $449 price on higher doses, pen or vial, requires a refill within 45 days, otherwise it goes to $499 at 7.5 mg and $699 from 10 mg up (11). Novo’s offer runs through December 31, 2026 and it says pricing will be updated after that (10). Lilly’s page lists no end date.

Both routes need a prescription. Novo’s prices apply when it is filled through NovoCare Pharmacy or with its savings offer (10). If you have insurance, check coverage and prior authorization first, since a covered fill beats any cash price. My cash pay prices post tracks the full ladder, including Medicare and the other federal programs.

Pills as a way out

Needles and syringes are part of why some people used compounded vials in the first place, and now there are two oral choices. Wegovy tablets start at 1.5 mg daily for 30 days, then 4 mg, then 9 mg, then 25 mg (6). Foundayo starts at 0.8 mg, steps to 2.5 mg after at least 30 days, then 5.5 mg, with room to 9, 14.5, or 17.2 mg (9). The Wegovy label does include a rule for moving from the 2.4 mg injection to the 25 mg tablet. Nothing in either label covers moving from a compounded injection, so the same logic applies: start at the bottom unless there is a good reason not to (6,9). I compared the two pills in Foundayo vs. the Wegovy Pill.

For most people it comes down to two things, preference and coverage. If insurance will help pay for Foundayo or the Wegovy pill, that is probably the most important deciding factor. If the patient is paying cash, that changes the math. And if someone doesn’t like injections, a pill usually makes more sense, as long as it is affordable and it keeps them on the medication.

Gray-market sellers and “research use” vials

When a compounded supplier folds, the next search result is often worse. FDA has warned companies that sold semaglutide, tirzepatide, and related peptides falsely labeled “for research purposes” or “not for human consumption” while supplying dosing instructions to consumers. It also says it is aware of counterfeit Ozempic, and advises buying only from state-licensed pharmacies (5). A price far below the brand cash prices above is the tell. Use FDA’s BeSafeRx tools if you are unsure about a site.

The same caution covers telehealth ads. FDA’s position is that compounded drugs are not FDA-approved (3), so a site promising “the same as Wegovy” is making a claim the agency has already penalized.

If you are the patient

Do not stretch your last vial to bridge the gap, and do not mix products. Photograph the label now, write down your last dose date, and book the switching visit before you run out. Ask your prescriber which brand product fits your coverage and budget, and expect a lower starting dose than you were on.

If you are the clinician

Document the compounded product, the pharmacy, the last dose date, and your reasoning for the starting dose, since no label supports a direct conversion. Counsel on the GI risk of reinitiation (6,7). Remember that state-licensed pharmacies that are not outsourcing facilities are not required to report adverse events to FDA, so your MedWatch report may be the only one (5).

The Bottom Line

Moving from compounded semaglutide or tirzepatide to Wegovy, Zepbound, or an oral option means a new prescription and a starting dose chosen for you, because compounded doses do not convert cleanly to brand doses.

Gap length and certainty drive the choice. A short gap on a verified, well-tolerated dose can be matched. A longer gap or an uncertain vial points toward the label starting dose and a four-week-step climb. Costs for the brand products are lower than they were, and the pills give needle-averse patients a path. Avoid gray-market sellers entirely.

Sources

U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (current as of April 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. April 30, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
U.S. Food and Drug Administration. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. March 3, 2026. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center: case series. J Am Pharm Assoc (2003). 2023;63(5):1643-1645. PMID 37392810. https://pubmed.ncbi.nlm.nih.gov/37392810/
U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Wegovy (semaglutide) injection and tablets, prescribing information (revised June 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
Zepbound (tirzepatide) injection, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
Eli Lilly Medical Information. What should a patient do if they miss a dose of Zepbound (tirzepatide)? https://medical.lilly.com/us/products/answers/what-should-a-patient-do-if-they-miss-a-dose-of-zepbound-tirzepatide-209169
Foundayo (orforglipron) tablets, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
Novo Nordisk. NovoCare: Wegovy savings and self-pay options. https://www.novocare.com/wegovy/savings-card.html
Eli Lilly and Company. Zepbound savings and insurance options. https://zepbound.lilly.com/savings

A row of worn cast iron kettlebells on a gym floor

What Happens If You Stop Taking a GLP-1?

On October 16, 2026 By Dr. Scott RennieIn Weight Loss & Metabolic HealthLeave a comment

Somebody asks me this almost every week, usually some version of the same sentence. “How long do I have to stay on this?”

It is a fair question and it deserves a straight answer rather than a lecture. So here is what the data says happens, what I do about it, and the handful of situations where I think stopping is the right call.

Why you want to stop matters more than the fact that you want to stop

The first thing I ask is why.

The answers cluster into three groups, and they lead to three completely different conversations. Some people have hit their goal and believe they can hold it from here on their own. Some are looking at the monthly cost and doing math. And some are uneasy about taking any medication for years on end, the same way people feel about a blood pressure pill or a statin.

None of those are unreasonable. But the plan for a patient who cannot afford the drug looks nothing like the plan for a patient who is worried about what it is doing to them over a decade, and lumping them together as “wants to stop” wastes the visit.

What the evidence actually shows

The honest version is that most of the weight comes back, and it comes back faster than people expect.

The best synthesis we have is a 2026 systematic review and meta-regression in eClinicalMedicine that pooled 48 studies (1). About 60 percent of the weight lost during treatment is regained within 52 weeks of stopping. The curve is steep early, slows, and flattens out around 60 weeks, with regain plateauing near 75 percent of what was lost. Read the other direction, roughly a quarter of the loss is still there.

The individual trials tell the same story. In the STEP 1 extension, participants had lost 17.3 percent of body weight on semaglutide. A year after the drug and the lifestyle support both stopped, they had regained 11.6 percentage points, leaving a net loss of 5.6 percent, and 48 percent were still at least 5 percent below where they started (2). In SURMOUNT-4, people who came off tirzepatide regained about 14 percent over the following year while those who stayed on lost another 6.7 percent, and 82 percent of the group that stopped gave back more than a quarter of their loss (3).

Here is the part that gets left out of the headlines, and the part I care about more than the scale. The metabolic improvements unwind first. Around 70 to 80 percent of the blood pressure improvement is gone within 12 weeks of stopping. About half of the HbA1c improvement is back by 8 to 12 weeks (1). The weight takes a year to come back. The blood pressure takes three months.

That ordering is the reason I do not treat stopping as a neutral event in someone with hypertension or diabetes.

It is physiology, not a character flaw

I want to be clear about what that regain represents, because patients are brutal with themselves about it.

These drugs work on appetite signaling. Take the drug away and the signaling returns to where it was, which means hunger returns to where it was. The body defends the higher weight. Regaining is the expected biological result of removing the treatment, not evidence that somebody got lazy in month four.

I say this out loud in visits because the shame around regain is what stops people from coming back and restarting when they need to.

Most people stop anyway

Worth knowing: stopping is the norm, not the exception.

In a cohort of 125,474 adults starting these medications, 46.5 percent of those with type 2 diabetes and 64.8 percent of those without had stopped within a year (4). An analysis of 60,000 insured patients presented at ENDO 2026 found about four in ten stopped in the first year, and nearly six in ten by two years (5).

But look at what happens next in that same data. Of the people who stopped, 41.5 percent restarted within a year and 58 percent within two (5). This is not a drug people take once and abandon. It is a drug people fall off and climb back onto, usually after the weight starts coming back.

One more number, and it is the one that changed how I think about this. An integrated health system that added structured pharmacist onboarding and real follow-up got its one-year discontinuation rate down to 3.9 percent (6). Compare that to the 46 to 65 percent above. Most of the stopping in this country is not a drug problem. It is an access, cost and support problem.

What I actually do: lower the dose rather than stop

When somebody has reached a healthy weight, my preference is not to stop the medication. It is to lower the dose to the amount that holds the weight steady instead of the amount that keeps driving it down.

I will say plainly that the evidence here is thin. There are no randomized trials of tapering or maintenance dosing after weight loss, only small observational reports (7). So this is clinical judgment rather than a protocol, and I tell patients that.

What I like about it is that it answers the three concerns at once. It costs less. It involves less drug for people who are uneasy about long-term exposure. And it keeps the appetite brake partly engaged, which is the thing that actually prevents the rebound.

When the reason is cost

This is the most common real reason, and it has the most workable solutions.

First, the cash-pay programs. Eli Lilly and Novo Nordisk both sell direct now, and the prices are meaningfully better than they used to be. For a lot of patients that alone closes the gap.

Second, insurance, which is more winnable than people assume. If a patient carries a weight-related condition, and most do, there is often a path to coverage. Diabetes, prediabetes, hypertension, high cholesterol, GERD, obstructive sleep apnea. Those are not footnotes. They are the clinical justification that gets a prior authorization approved. It is worth the paperwork.

Third, switch the drug rather than abandon the class. Semaglutide instead of tirzepatide. Liraglutide instead of either. Not identical, but real.

Fourth, Medicare, and this is the part most patients have not heard. Part D still cannot pay for a drug prescribed for weight loss alone, because that exclusion sits in the statute and the 2025 attempt to reinterpret it was never finalized. What changed is the Medicare GLP-1 Bridge, which went live July 1, 2026 and runs through the end of 2027. It puts Foundayo, Wegovy and the Zepbound KwikPen at $50 a month for eligible beneficiaries (8). The Zepbound vials and single-dose pens are not in it, which is catching people out. If a patient was told no before last summer, that answer is worth getting again.

And if none of that works, we move to what is affordable. Bupropion and naltrexone as generics. Metformin. These are not equivalent to a GLP-1 and I do not pretend otherwise. They are considerably better than nothing, which is the actual alternative on the table.

Protecting muscle

If weight is going to move in either direction, I want as much of it as possible to be fat.

I target protein intake around 1.5 grams per kilogram. I want resistance training at least twice a week, and 30 minutes of aerobic activity five days a week. That applies while losing, while maintaining, and especially after stopping.

The concern worth naming is that we do not know whether regained weight comes back in the same proportions it left. If fat returns faster than muscle, somebody can land at their old weight with worse body composition than they had before treatment. The data on that is genuinely unsettled, so I am not going to overstate it. The defense is the same either way: protein and resistance training.

When I bring up the long-term question, and why not sooner

This is where I part company with a lot of advice.

I do not open with “this is a lifelong medication.” Early on, we do not yet know whether the drug will even work for this person, and plenty of patients arrive with reservations already sitting in the back of their minds. Leading with a life sentence can talk somebody out of a treatment that might have changed their health, before anyone knows if it helps.

So I raise it as we approach maintenance, when there is something real to discuss: this is working, here is what holding onto it looks like.

When I support stopping

Not every stop is a mistake. I will back the decision in a patient who becomes pregnant, who cannot tolerate the side effects, who genuinely cannot afford it after we have worked the options, or who is not able to use it safely. That last one covers skipping the lab work, taking it in ways it was not prescribed, or developing disordered eating patterns such as bingeing and purging or restricting toward anorexia. It also covers losing more weight than is healthy and not sticking to the maintenance plan.

In those situations stopping is the correct medical decision, not a failure of resolve.

Restarting

People restart. It is common, and I treat it as a normal part of the course rather than a setback.

If somebody has been off for more than about a month, we go back to introductory dosing and step up again. Restarting at the dose you left off at is how people end up with a week of nausea they did not need to have.

For clinicians

Three things worth carrying into your own visits.

Ask the why before you negotiate the how, because cost, goal attainment and long-term safety worry need different responses.

Counsel on the cardiometabolic rebound, not only the weight. Your patient with hypertension will give back most of their blood pressure improvement inside three months, which is a faster and more clinically meaningful change than the scale (1).

And treat the discontinuation statistics as a system signal rather than a patient-adherence story. A 3.9 percent one-year discontinuation rate in a supported program, against 46 to 65 percent in the broader population, tells you where the problem actually lives (4,6).

The Bottom Line

Stopping a GLP-1 means most of the weight comes back, typically around 60 percent of it within a year, with the blood pressure and blood sugar improvements unwinding much faster than that.

That is physiology rather than failure. If you have reached a healthy weight, lowering the dose is usually a better move than stopping outright. If cost is the problem, there is more room to work than most people realize, between cash-pay pricing, prior authorization based on the conditions you already have, switching agents, and the Medicare GLP-1 Bridge if you are on Medicare. And if you do stop, protect your muscle, and come back without embarrassment if the weight starts climbing. Restarting is common and it works.

Sources

Budini B, Luo S, et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine. 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13043475/
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Internal Medicine. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2841273
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829779
Endocrine Society. More than half of those who stop GLP-1s restart within a year. ENDO 2026, presented June 14, 2026. https://www.endocrine.org/news-and-advocacy/news-room/2026/sontha-press-release-endo-2026
Health System Pharmacies Keep Patients on GLP-1 Therapy. American Journal of Managed Care. https://www.ajmc.com/view/health-system-pharmacies-keep-patients-on-glp-1-therapy
Scripps. Patients Maintained Weight Loss After Reducing GLP-1 Treatment Frequency. https://www.scripps.org/news_items/8102-scripps-patients-maintained-weight-loss-after-reducing-glp-1-treatment-frequency
Medicare GLP-1 Bridge: Information for Providers. Centers for Medicare & Medicaid Services. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers

A wooden staircase with oak treads beside a white wall, lit by soft morning sunlight in a quiet hallway

Wegovy 7.2 mg: Who Should Consider the Higher Dose?

On July 31, 2026September 11, 2026 By Dr. Scott RennieIn Weight Loss & Metabolic HealthLeave a comment

Wegovy just got a new top rung on the ladder. In March of this year, the FDA approved a higher, 7.2 mg dose of semaglutide, marketed as Wegovy HD, for adults with obesity or overweight. This is a new ceiling on a drug we already know well. Same drug. Higher rung. I think it’s worth walking through what the data actually shows before deciding who in your practice, or mine, is a good candidate for it.

The approval leaned on two trials, STEP UP and STEP UP T2D, both 72-week phase 3 studies. In STEP UP, which enrolled adults with obesity but without type 2 diabetes, patients on 7.2 mg lost an average of 20.7% of body weight, compared with 15.6% on the standard 2.4 mg dose and 3.9% on placebo, a meaningful jump and not a marginal one. Almost a third of patients on the higher dose, 31.2%, lost a quarter or more of their starting body weight. In the companion trial, STEP UP T2D, which looked at patients with obesity and type 2 diabetes, the numbers were lower but still substantial: 14.1% average weight loss, with about a fifth of patients losing 20% or more. That gap between the diabetes and non-diabetes cohorts isn’t surprising. We see it consistently with GLP-1 therapy, and it’s a good reminder to set expectations differently for patients with T2D up front.

Here’s the part that matters most for how I’ll actually use this in practice: Wegovy HD isn’t a starting dose. The label requires that a patient have already tolerated 2.4 mg for at least four weeks before stepping up, and the escalation is meant for patients where additional weight loss is clinically indicated, meaning the 2.4 mg dose hasn’t gotten them where they need to be. So the ideal candidate is someone who’s already on semaglutide, tolerating it reasonably well, but has plateaued short of their goal or still has a lot of excess weight to lose relative to their comorbidities. Think of a patient who’s been on 2.4 mg for six months, lost maybe 10-12% of body weight, tolerates the GI side effects fine, but still has a BMI well into obesity range with sleep apnea or hypertension that hasn’t fully responded. That’s the kind of case where I’d bring up 7.2 mg. It’s not for someone just starting therapy, and it’s not for someone who’s struggling with nausea or GI symptoms at the lower dose. If they can’t tolerate 2.4 mg, going higher solves nothing.

Which brings up the safety side, because the tradeoff here is real.

Overall tolerability at the higher dose was described as similar to what’s been seen with 2.4 mg, with GI effects like nausea, vomiting, constipation, and abdominal pain remaining the most common complaints. But two numbers stood out to me. Dysesthesia, essentially altered or abnormal skin sensation, occurred in 22% of patients on 7.2 mg versus 6% on 2.4 mg and 0.3% on placebo. That’s not a side effect I’d been counting on discussing much with patients on standard-dose semaglutide, and it’s one I’ll need to specifically ask about at follow-up visits once patients move up. I’ve seen the same pattern in my own patients, the ones who dose escalate quickly on standard Wegovy dosing, well before anyone gets near 7.2 mg. The trial data and my own visit notes agree on that one. Dose reductions due to adverse events were also more common at the higher dose, 18.5% versus 12.4% on 2.4 mg, and discontinuation due to side effects ran around 5.4%. The higher dose isn’t a free upgrade. You’re trading tolerability for more weight loss, and that’s a conversation to have explicitly with the patient rather than assume they’d automatically want the escalation.

From a practical standpoint, Wegovy HD is expected to be available through pharmacies and telehealth channels starting in April, delivered in a single-dose pen. I don’t think this changes how I approach a new patient starting on semaglutide at all, the same titration principles from 2.4 mg still apply. What it does is give me another option for the subset of patients who’ve done well but not well enough, and who’ve shown they can handle the medication without major GI intolerance. That’s a narrower group than “everyone on Wegovy,” and I’d resist the urge, mine or a patient’s, to jump to the higher dose just because it’s now available. The data supports it for the right patient. It doesn’t support treating it as the new default starting point.

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources:

FDA approves high-dose Wegovy 7.2 mg for adults with obesity, Healio: https://www.healio.com/news/endocrinology/20260319/fda-approves-highdose-wegovy-72-mg-for-adults-with-obesity

FDA approves Novo Nordisk’s new Wegovy HD injection, delivering the highest weight loss to date for a Wegovy injection, PR Newswire: https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.html

STEP UP Trial Shows Higher Dose of Wegovy Produces Significant Weight Loss in Adults With Obesity Without Diabetes, Applied Clinical Trials Online: https://www.appliedclinicaltrialsonline.com/view/wegovy-weight-loss-obesity-diabetes

Digital scale showing weight comparison of green and purple capsules in milligrams

Foundayo vs. the Wegovy Pill: Comparing the Two New Weight Loss Pills

On July 31, 2026November 7, 2026 By Dr. Scott RennieIn Weight Loss & Metabolic HealthLeave a comment

For years, if you asked me “is there a pill version of these weight-loss drugs?”, the honest answer was no, not really. That changed twice, four months apart. If you haven’t been following closely, the options today look nothing like they did two years ago.

A quick note on names first, since patients ask me this a lot. The Lilly drug some people have heard called “Fonday-o” is orforglipron. The FDA approved it on April 1, 2026, under the brand name Foundayo (1). Before that, on December 22, 2025, the FDA approved a 25 mg oral semaglutide tablet under the Wegovy name (2). GLP-1 medicines help control appetite and blood sugar, and that tablet was the first pill version of one approved for long-term weight management. Both are real, both are approved, and both can be prescribed today.

Both full prescribing labels are now public, and they differ in ways that decide the choice for a lot of people. Most of those differences have nothing to do with how much weight each one takes off.

Why the two pills work so differently in your body

Semaglutide is a peptide, which is a small chain of amino acids, the building blocks of proteins. Your stomach is very good at breaking down peptides, which is exactly why semaglutide originally had to be given as a shot.

Novo Nordisk’s solution was to add an ingredient called SNAC that helps the drug get absorbed before your stomach destroys it. According to a review in the journal Clinical Diabetes, SNAC does three things at once (3). It changes the local acidity around the tablet as it dissolves, it briefly protects the drug from a stomach enzyme called pepsin, and it helps the drug cross the stomach lining into your bloodstream. The absorption happens in the stomach itself rather than the intestines, which is unusual for a pill. The drug essentially enters your body right where the tablet is sitting against your stomach wall.

That trick comes with a catch, and the label is specific about it (4). You take the tablet on an empty stomach in the morning with no more than four ounces of plain water. No other liquids. Swallow it whole, and wait at least 30 minutes before you eat, drink anything, or take any other oral medication.

Thirty minutes. Every morning. Before coffee.

Orforglipron works completely differently. It is a small molecule, meaning a stable chemical rather than a fragile peptide chain. It belongs to the same drug family, mimicking a natural gut hormone that reduces appetite, but with no peptide to protect it needs no absorption booster and carries no timing ritual. Its label says to take it once daily with or without food, and specifies no water restriction and no waiting period (5). For someone who works nights, or who already swallows six other pills at breakfast, that is the whole ballgame.

What the labels actually say, and why the number in your news feed is wrong

Most of the figures circulating online come from journal publications and press releases rather than from the approved labels. The label numbers are the ones your prescription is based on, so those are the ones I use.

For Wegovy tablets, the label reports a 64-week trial in 205 adults on the tablet against 102 on placebo, all with obesity or overweight plus a weight-related condition, with diabetes excluded (4). Average weight change was 13.6 percent down on the tablet and 2.4 percent down on placebo, a difference of 11.2 percentage points. Broken out by how much people lost: 76.3 percent lost at least 5 percent of their body weight versus 31.3 percent on placebo, 59.8 percent lost at least 10 percent versus 14.4 percent, 47 percent lost at least 15 percent versus 5.5 percent, and 27.9 percent lost at least 20 percent versus 3.1 percent.

For Foundayo, the label reports a 72-week trial in 3,127 adults without diabetes (5). Average weight change was 7.4 percent down at the 5.5 mg dose, 8.3 percent down at 9 mg, and 11.1 percent down at the maximum 17.2 mg dose, against 2.1 percent down on placebo. At 17.2 mg, 35.9 percent of patients lost at least 15 percent of their body weight, compared with 6 percent on placebo.

Put those side by side and the semaglutide tablet looks better, and I would be careful with that read. Different patients, different trial lengths, different placebo responses, and nobody randomized the same people to both. What is harder to wave away is the size of each evidence base. The semaglutide tablet’s label efficacy rests on 205 treated patients. Foundayo’s rests on 3,127. Both cleared the FDA, so both met the bar, but I have more confidence in how a drug behaves across a wide range of real people when the number in the trial is measured in thousands.

Here is the detail that confuses almost everyone who reads the news coverage. The approved Foundayo strengths are 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg, stepped up roughly every 30 days. The trial used a capsule at 1, 3, 6, 12, 24, and 36 mg. Those map onto each other in order, so the 17.2 mg tablet you can actually be prescribed is the 36 mg dose you read about. If your maximum dose sounds far smaller than the headline, that is why.

One thing I noticed reading the Foundayo label closely: the 14.5 mg strength is approved and dispensable, and it does not appear in the label’s efficacy table at all. You can be prescribed a dose with no published average weight loss attached to it. Not dangerous, just worth knowing if you end up parked there.

The only comparison anyone has run, and who paid for it

There is still no head-to-head trial of these two drugs in obesity. There is now an indirect comparison, published in Diabetes, Obesity and Metabolism in August 2026, which pulled individual patient data from the semaglutide tablet trial and aggregate data from the orforglipron trial and statistically adjusted for differences in sex, body weight and glucose status between the two populations (6).

It found oral semaglutide 25 mg ahead by 3.2 percentage points of body weight (95% confidence interval 5.9 to 0.4) and reported higher discontinuation with orforglipron, with an odds ratio of 4.1 for stopping due to any adverse event and 13.9 for stopping due to gastrointestinal side effects.

Five of the authors are Novo Nordisk employees and shareholders, two more work for a consultancy Novo paid to run the analysis, and Novo makes the drug that won. That does not make the result false. It does mean I apply a discount. The direction is plausible and roughly matches the gap between the two labels. The magnitude I would not quote to a patient as fact. And that gastrointestinal odds ratio of 13.9 has a confidence interval running from 2.0 to 96.0, which is another way of saying the study could not pin it down.

There is one true head-to-head, and it points the other way. In adults with type 2 diabetes, orforglipron beat oral semaglutide on weight loss (7). That trial used semaglutide at 7 mg and 14 mg, well under the 25 mg weight-management dose, in a different population, for a different purpose. It answers a different question than the one you are asking.

Birth control is the difference nobody mentions

This is the most actionable difference between the two drugs and it almost never comes up in the coverage.

The Foundayo label instructs patients on oral hormonal contraceptives to switch to a non-oral method, or to add a barrier method for 30 days after starting the drug and for 30 days after every dose escalation (5). Count the escalations. With six strengths, somebody climbing to the top dose is looking at several separate 30-day windows where their pill alone is not considered reliable. Non-oral hormonal contraception is not expected to be affected.

The Wegovy tablet label carries no equivalent instruction. Its pharmacokinetic studies found no clinically significant interaction with ethinyl estradiol and levonorgestrel (4).

For a woman in her twenties or thirties on a combined oral contraceptive who does not want a pregnancy, that single difference outweighs three percentage points of average weight loss. I bring it up before either drug gets prescribed, not after.

The other interactions that quietly decide this

Orforglipron is cleared through CYP3A4, and the label puts real fences around that (5). On a strong CYP3A4 inhibitor, the maximum Foundayo dose drops to 9 mg. Clarithromycin raised orforglipron exposure 3.5-fold in a study. Going the other way, carbamazepine cut exposure by 82 percent and efavirenz by 61 percent, so strong inducers are to be avoided and moderate ones need the dose pushed up while you watch whether it still works. Strong inhibitors that also block OATP1B, ritonavir being the example the label gives, are to be avoided outright. And simvastatin is capped at 20 mg a day alongside it.

The semaglutide tablet has a shorter list but one that matters in my practice. A single 600 mcg dose of levothyroxine taken with it produced a 33 percent rise in total thyroxine exposure (4). Add the 30-minute rule on top, which pushes every other morning medication back, and a patient on thyroid replacement plus a few other dailies has a genuine scheduling problem.

If someone comes to me on carbamazepine, or on ritonavir-boosted therapy, Foundayo is awkward enough that I start elsewhere. If someone is on levothyroxine and already struggles to take it correctly, I think hard before adding a second pill with its own empty-stomach window.

Side effects

Both drugs hit the gut, and both labels say so plainly.

Foundayo’s pooled safety data runs nausea at 26 percent, 34 percent and 35 percent across the 5.5, 9 and 17.2 mg doses against 10 percent on placebo (5). Vomiting climbs from 13 to 24 percent against 4 percent. Constipation runs 20 to 27 percent against 9 percent, and diarrhea 21 to 25 percent against 11 percent. Hair loss shows up at 4 to 5 percent against 2 percent, which patients ask me about more than the numbers would suggest.

The Wegovy tablet label describes side effects similar to the injection, and adds a few tablet-specific figures (4). Just under 7 percent of patients stopped the drug for an adverse reaction, against about 6 percent on placebo. Severe gastrointestinal reactions occurred in 2 percent of tablet patients and no placebo patients. Dysesthesia, meaning abnormal or unpleasant sensation, was reported in 5 percent of tablet patients and in nobody on placebo. That last one is not something I had on my radar before reading the label, and it is worth mentioning to a patient who calls about odd skin sensations rather than writing it off.

Both drugs carry a boxed warning about thyroid C-cell tumors and are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 (4)(5).

If you have heart disease, the answer is already made

Wegovy tablets carry an approved indication to reduce the risk of major adverse cardiovascular events, meaning cardiovascular death, non-fatal heart attack and non-fatal stroke, in adults with established cardiovascular disease and either obesity or overweight (4). The wording is identical to the injection’s.

Foundayo has no cardiovascular outcome indication. Its cardiovascular outcomes trial has not reported.

For a patient who has already had a heart attack or a stroke, that settles it. I go to semaglutide, and the only remaining question is tablet or injection.

How I actually choose

If you are the patient reading this, the useful question is not which drug is stronger. It is which one you will still be taking in a year. The 30-minute waiting period for the semaglutide tablet sounds minor when we talk it through on a video visit, and it trips people up in real life. I have watched patients lose ground on oral semaglutide because weekday mornings made the timing rules impossible to follow, and the drug cannot work from inside the bottle. If your mornings are chaotic, say so out loud when we talk. That is clinical information, not an excuse.

If you are a prescriber, I would frame the choice around four things before efficacy. Established cardiovascular disease points to semaglutide on the label. An oral contraceptive points away from orforglipron, or at least commits you to counseling a barrier method through every escalation. A CYP3A4 problem, especially an enzyme inducer, makes orforglipron hard to dose. Levothyroxine and a crowded morning pill box make the semaglutide tablet hard to take. What is left after those four filters is usually a clear answer, and in my experience the efficacy gap is the least useful thing to lead with.

What this costs right now

Both manufacturers run tiered self-pay pricing that starts low at the smallest dose and rises as you titrate up, and both have promotional rates on their lower strengths that are scheduled to end on December 31, 2026. Because these terms change faster than I can keep a blog post current, check the two official pages directly rather than trusting a number you read anywhere, including here: LillyDirect for Foundayo (8) and NovoCare for Wegovy (9).

What I can tell you from prescribing both is operational. I haven’t run into a prior-authorization fight or a stocking problem with Foundayo yet. Most of what I prescribe goes through LillyDirect on cash pay, because it has been one of the cheaper options on the table. Patients who have real insurance coverage tend to ask for injectable Wegovy or Zepbound instead, and I do not talk them out of it. For a fuller breakdown of cash prices across the whole class, including the injections, see my separate post on cash pay options.

The Bottom Line

Two pills, both approved, both effective, and the deciding factors are mostly not about weight loss. The semaglutide tablet takes off a bit more weight in the label data, carries a cardiovascular indication, and demands an empty stomach and a 30-minute wait every single morning. Foundayo asks nothing of your schedule, has a far larger trial behind it, and brings a contraception instruction and a list of drug interactions that rule it out for some people entirely.

Bring your actual medication list and your actual morning routine to the visit. Those two things will pick the drug faster than any comparison chart.

Sources

1. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss (Eli Lilly): https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

2. FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults (PR Newswire): https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html

3. Current Understanding of SNAC as an Absorption Enhancer: The Oral Semaglutide Experience (Clinical Diabetes, American Diabetes Association): https://diabetesjournals.org/clinical/article/42/1/74/153538/Current-Understanding-of-Sodium-N-8-2

4. WEGOVY (semaglutide) injection and tablets, US prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

5. FOUNDAYO (orforglipron) tablets, US prescribing information (Eli Lilly): https://uspl.lilly.com/foundayo/foundayo.html

6. Michalak W, Bøg M, Bendixen T, Chowdhury R, Cowley P, Laugesen C, et al. Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. Diabetes, Obesity and Metabolism. 2026;28(8):7247-7256: https://pubmed.ncbi.nlm.nih.gov/42225305/

7. Orforglipron Outperforms Oral Semaglutide in Head-to-Head Type 2 Diabetes Trial (AJMC): https://www.ajmc.com/view/orforglipron-outperforms-oral-semaglutide-in-head-to-head-type-2-diabetes-trial

8. Foundayo self-pay pricing (LillyDirect): https://www.lilly.com/lillydirect/foundayo

9. Wegovy self-pay pricing (NovoCare): https://www.novocare.com/

10. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (New England Journal of Medicine, ATTAIN-1): https://www.nejm.org/doi/full/10.1056/NEJMoa2511774

A pharmacist standing in front of shelves of medicines

Compounded Semaglutide and Tirzepatide: What to Know Now

On October 17, 2025September 29, 2026 By Dr. Scott RennieIn Weight Loss & Metabolic HealthLeave a comment

When patients ask me about compounded weight loss drugs like semaglutide and tirzepatide, I take a deep breath. The topic is complicated and keeps changing. I won’t just tell patients to avoid them. They’re already looking for these options, and my job is to help them navigate the risks safely.

Dr. Beverly Tchang’s “swim safely” analogy fits well. We can’t stop people from diving into the ocean of compounded products, but we can at least give them floaties: information, caution, and tools to make better decisions. (Tchang, Medscape)

Here’s how I explain it to patients and colleagues, updated with the most recent data.

Why compounded versions exist

When semaglutide and tirzepatide injections were in short supply a few years ago, patients turned to compounding pharmacies that offered custom formulations, often at a lower price. (GoodRx)

In late 2024, the FDA ended the declared shortage of tirzepatide. (Stat News) By early 2025, semaglutide (Ozempic and Wegovy) followed. Once the shortages ended, enforcement ramped up against compounded versions. (GoodRx)

Now, compounded versions are only legal in narrow circumstances, such as when a patient has a medical need that can’t be met by an approved product. (GoodRx)

In December 2024, the FDA sent warning letters to several companies selling unapproved GLP-1 drugs labeled “for research use only.” (Reuters) Some of these contained no active ingredient, incorrect salt forms, or inconsistent potency. (Verywell Health)

Key risks and what to look for

Not all compounding pharmacies operate at the same standard. A friendly local pharmacist doesn’t necessarily mean the product is safe. Dr. Tchang’s checklist gives a good framework for evaluating any compounded GLP-1 medication. A simplified version: look for a pharmacy where the medication is prescribed by a licensed provider, there are no disciplinary actions on file, the pharmacy has been in business for more than a year, only semaglutide base is used (not a salt form), and the facility is FDA-registered or FDA-inspected; it should also be able to ship sterile drugs safely to all 50 states.

If a compounding pharmacy cannot meet these criteria, that’s a red flag. Ask directly for documentation. If they can’t provide it, walk away.

Some compounders also mix in vitamins or preservatives to make their product “different” from the brand name; that may sound harmless, but combining untested additives with peptides can change how the drug behaves. (GoodRx)

A few are promoting oral or sublingual forms of semaglutide and tirzepatide. These seem attractive for patients who don’t like injections, but they haven’t been validated in clinical trials, and absorption is unpredictable. (Omada Health)

Even small changes in formulation or dosing can interrupt treatment and cause rebound weight gain or side effects.

How I approach this with patients

When a patient says, “I found a compounding pharmacy that sells it for half the price,” I acknowledge their concern. Access and cost are real issues. But I explain that the regulatory situation has changed. If an FDA-approved version is available, that’s the standard we should use first.

I encourage patients to ask the pharmacy for their certificate of analysis, sterility test results, and ingredient source; if the pharmacy hesitates or says it’s proprietary, that’s enough reason to stop.

One patient of mine was on a compounded semaglutide microdose that wasn’t commercially available, at least as she described it to me. I never could pin down what she was actually getting. The compounder wouldn’t release potency data either. We moved her to a low-dose commercial version instead. Weight loss slowed a little. Safety and consistency improved, and I knew what was in the pen.

We also reviewed manufacturer assistance programs and insurance coverage. Many patients don’t realize that drug makers often cap out-of-pocket costs for brand medications; cost confusion is one of the biggest drivers behind compounded use.

The FDA’s BeSafeRx campaign

The FDA has an ongoing public safety campaign called BeSafeRx, designed to help patients and providers verify the legitimacy of online pharmacies and compounded drug sources; it offers tools to check pharmacy licenses, identify red flags, and report suspicious products.

It’s a good resource for anyone considering buying compounded or online medications; I often share it directly with patients so they can see what trustworthy sourcing looks like.

You can find the BeSafeRx information at:

https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information

What’s changed recently

The REDEFINE trial (NEJM, 2025) studied cagrilintide combined with semaglutide (CagriSema) and showed about 20.4 percent weight loss over 68 weeks, compared with 14.9 percent with semaglutide alone; that kind of data will shape treatment algorithms going forward. GoodRx reports that the FDA’s grace period for compounding GLP-1s has officially ended for both tirzepatide and semaglutide, though some pharmacies still market “custom” or “non-identical” formulations, and regulators are watching closely.

Approach this without judgment if you’re a clinician. Patients are trying to find affordable solutions. And they often trust what they see on social media more than official channels; we can help most by staying informed, asking questions, and documenting carefully. Patients should be cautious for a different reason. Ask your provider to review any compounded medication before you use it, make sure your pharmacy meets every item on that checklist, and use resources like the FDA’s BeSafeRx to verify safety.

Knowledge and transparency remain the best safeguards.

Wegovy and Zepbound Cash Pay Prices Without Insurance (2026 Update)

On September 14, 2025September 20, 2026 By Dr. Scott RennieIn Weight Loss & Metabolic HealthLeave a comment

Updated September 2026: Self-pay prices for Wegovy and Zepbound have both come down since this post first ran, a new oral option (Foundayo) now has its own cash price through Lilly, and a federal deal put a government storefront, TrumpRx.gov, and a temporary Medicare benefit into the middle of the picture.

Patients and colleagues ask me often about the cost of GLP-1 medications when insurance does not cover them. Wegovy, Zepbound, and now Foundayo are all FDA approved for chronic weight management, and I prescribe all three by video visit. The barrier that brings people to this post hasn’t changed: their plan excludes the drug category outright, no prior authorization appeal is going to fix that, and the retail cash price at a corner pharmacy is still well over a thousand dollars a month (10).

What Actually Changed

A year ago the only option was NovoCare’s flat $499 rate for Wegovy and Lilly’s roughly $500 rate for Zepbound. In 2025 I had a patient who had already tried to fill Wegovy at a local pharmacy. The pharmacist quoted her a cash price over $1,300. She couldn’t afford that. Under NovoCare’s program as it existed then, she could have her prescription sent to NovoCare Pharmacy for $499 a month instead. That flat rate is gone now. Both companies have rebuilt their self-pay pricing since then, and a November 2025 deal between the White House and both manufacturers pushed cash prices down further and set the stage for a new Medicare benefit (8). What you get in September 2026 is a tiered price ladder instead of one flat number, and most doses cost less than they did a year ago.

Wegovy: Injection and Pill, Two Different Price Ladders

NovoCare Pharmacy remains Novo Nordisk’s direct-to-consumer channel for patients paying cash. If your plan covers Wegovy, a separate commercial savings card is the better deal and can bring a copay down near zero; that’s a different program from what’s below. As of this September, the injectable pen runs $349 a month for the standard dose range and $399 a month for the newer HD 7.2 mg strength, with a $199 introductory rate for a patient’s first two monthly fills that Novo has said will hold through the end of 2026 (1). The oral tablet, approved in December 2025 and launched in January 2026 as the first pill-form GLP-1 for obesity, is priced in three tiers: $149 for the starter dose, $199 for the next step up, and $299 once a patient reaches a maintenance strength (1). Both require the prescription to be filled through NovoCare specifically. A local pharmacy handed the same script will still quote the full list price, somewhere north of $1,300 (10).

Zepbound: LillyDirect’s Vial and Pen Pricing

Lilly runs a comparable program under LillyDirect, and the vial and the single-patient-use KwikPen are priced identically by dose: $299 for the 2.5 mg starting dose, $399 at 5 mg, and $449 across the 7.5 to 15 mg range (4). That top tier has a catch: the $449 rate only holds if the patient refills within 45 days of the last delivery. Miss the window and the price reverts to $499 for 7.5 mg or $699 for the higher strengths (4, 5). It is an easy detail to overlook when a patient is titrating slowly or pauses therapy for a few weeks.

Foundayo: The Oral Option From Lilly

Foundayo (orforglipron) is Lilly’s oral small-molecule GLP-1, approved this spring and priced through the same LillyDirect infrastructure: $149 at the 0.8 mg starting dose, $199 at 2.5 mg, and $299 across the maintenance range from 5.5 mg up through 17.2 mg (6). Lilly’s own pricing page wasn’t accessible when this update was written, so these numbers come from a pharmaceutical trade publication that reported them the week Foundayo launched. Check the live page before quoting a patient a number.

Medicare, Medicaid, and the Federal Programs

Government coverage intersects this topic in two separate ways, and they are easy to conflate.

The first is eligibility for the manufacturer self-pay programs themselves, and the two companies handle it differently. NovoCare’s own program terms allow a patient enrolled in Medicare, Medicaid, TRICARE, or another government plan to use the Wegovy or Wegovy-pill self-pay price, as long as they pay the full cash price, do not bill their government coverage for it, and do not count it toward a deductible or Part D out-of-pocket total (2). LillyDirect’s Zepbound Self Pay Journey Program works the other way: its terms require that a patient not be enrolled in any state or federal government healthcare program at all, including Medicare, Medicaid, TRICARE, and VA, to use the self-pay price (4). I could not find published eligibility terms for Foundayo’s self-pay program, so I’m not assuming it follows Zepbound’s rule.

The second is an actual Medicare drug benefit, the Medicare GLP-1 Bridge, a temporary demonstration built from the same November 2025 deal. It started July 1, 2026 and runs through December 31, 2027. It covers Foundayo, all formulations of Wegovy, and the Zepbound KwikPen, though not the Zepbound vial, for a $50 monthly copay under Medicare Part D. A beneficiary has to meet BMI and health-condition criteria, such as type 2 diabetes or cardiovascular disease, and the prescriber has to get it prior-authorized (11). This runs through a regular pharmacy claim, not a manufacturer cash-pay program, and has been active a little over two months.

TrumpRx.gov, the federal storefront that launched in February, lists the Wegovy pill at $149 a month and the Wegovy pen at $199, alongside Ozempic at $199 (7). The pen price matches NovoCare’s own first-two-fills introductory rate rather than the ongoing $349 rate, and the site appears to route orders through the same manufacturer pharmacies rather than operating as an independent seller.

Current Self-Pay Prices at a Glance

Product	Dose / Tier	Self-Pay Price	Notes
Wegovy pen (NovoCare)	0.25 to 2.4 mg	$349/mo	$199/mo for first two fills through Dec 31, 2026
Wegovy pen HD (NovoCare)	7.2 mg	$399/mo
Wegovy pill (NovoCare)	Starter dose	$149/mo
Wegovy pill (NovoCare)	Step-up dose	$199/mo
Wegovy pill (NovoCare)	Maintenance dose	$299/mo
Zepbound vial or KwikPen (LillyDirect)	2.5 mg	$299/mo
Zepbound vial or KwikPen (LillyDirect)	5 mg	$399/mo
Zepbound vial or KwikPen (LillyDirect)	7.5 to 15 mg	$449/mo	Requires refill within 45 days, otherwise $499 to $699/mo
Foundayo (LillyDirect)	0.8 mg starter	$149/mo	Not independently confirmed on Lilly’s site; see notes
Foundayo (LillyDirect)	2.5 mg	$199/mo	Same caveat
Foundayo (LillyDirect)	5.5 to 17.2 mg maintenance	$299/mo	Same caveat
Medicare GLP-1 Bridge (Part D)	Foundayo, Wegovy, Zepbound KwikPen only	$50/mo copay	Started July 1, 2026; requires prior authorization and BMI/condition criteria
TrumpRx.gov	Wegovy pill	$149/mo	Mirrors NovoCare price
TrumpRx.gov	Wegovy pen	$199/mo	Introductory rate only
Retail list price, no program	Wegovy	~$1,349 to $1,650/mo	GoodRx average
Retail list price, no program	Zepbound	~$1,060 to $1,271/mo	GoodRx average

The Compounding Chapter Is Closed

Patients still ask about compounded semaglutide and tirzepatide. The versions that filled the gap during the 2023 to 2024 shortage are no longer a legitimate mass option. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and the grace periods for 503A and 503B compounders to wind down ended by mid-2025 (9). This April, FDA moved to formally strike both drugs from the bulk compounding list, closing the loophole some pharmacies had used to keep producing modified formulations. A narrow carve-out remains for pharmacies filling four or fewer prescriptions of a drug per month, but that isn’t the shortage-era product (9). If a telehealth company is still advertising a cheap compounded semaglutide or tirzepatide product, ask hard questions before filling it.

For Patients

Eligibility for the self-pay price is not the same across both companies, and it is worth reading the actual terms rather than assuming. NovoCare allows patients with Medicare, Medicaid, TRICARE, or VA coverage to use the Wegovy self-pay price if they pay cash and don’t bill their government plan for it. LillyDirect’s Zepbound self-pay program excludes anyone enrolled in a government health plan regardless of how they intend to pay. If you have Medicare Part D and meet the clinical criteria, ask your prescriber about the GLP-1 Bridge instead; it covers Foundayo, Wegovy, and the Zepbound KwikPen for a $50 copay. Whichever route applies to you, the prescription has to be routed to the correct pharmacy to get that price. Handing the same script to your neighborhood pharmacist and expecting the discounted rate will not work.

For Clinicians

Both LillyDirect and NovoCare are really good in my experience. The paperwork is less than most insurance companies require, and both platforms are quick to get medications out to patients. I like them equally. Two details are worth flagging with patients: the refill-window trap on Zepbound’s top-tier pricing, and the fact that TrumpRx’s price for the Wegovy pen is a promotional rate rather than the standing one. Setting expectations for month three matters as much as month one. Eligibility terms differ by manufacturer too, so confirm which program a given patient’s coverage actually qualifies for before writing the prescription.

The Bottom Line

Wegovy and Zepbound both cost less than they did a year ago, and two oral options now sit at the bottom of the price range. A $199 to $349 monthly price for Wegovy, or $299 to $449 for Zepbound, is a different number than $1,300 a month, even though it is still a real expense for most households. Whether a government-insured patient can use self-pay pricing depends on the manufacturer: NovoCare permits it, LillyDirect does not, and qualifying Medicare Part D enrollees have a separate $50 option through the GLP-1 Bridge. None of it works if the prescription goes to the wrong pharmacy. Confirm the current terms before committing to a plan; this class of drug has changed its pricing and its rules more than once a year for three years running.

Sources

Novo Nordisk, NovoCare Pharmacy self-pay pricing for Wegovy, novocare.com/patient/medicines/wegovy.html, accessed September 11, 2026.
Novo Nordisk, NovoCare Pharmacy Terms and Conditions of Use (self-pay eligibility for government-insured patients), novocare.com/eligibility/pharmacy.html, accessed September 11, 2026.
Novo Nordisk, “Novo Nordisk introduces NovoCare Pharmacy, lowering cost of all doses of FDA-approved Wegovy (semaglutide) to $499 per month,” prnewswire.com, August 5, 2025 (program launch, price since superseded, cited for history only).
Eli Lilly, Zepbound coverage, savings, and self-pay eligibility, zepbound.lilly.com/hcp/coverage-savings, accessed September 11, 2026.
Eli Lilly, “Lilly lowers the price of Zepbound (tirzepatide) single-dose vials,” investor.lilly.com, accessed via search September 11, 2026 (direct page fetch timed out; figures cross-checked against source 4).
PharmExec, “FDA Approves Foundayo Under National Priority Voucher Program,” pharmexec.com/view/fda-approves-foundayo-under-national-priority-voucher-program, April 1, 2026.
TrumpRx.gov, GLP-1 medication pricing listing, trumprx.gov, accessed September 11, 2026.
NBC News, “Trump administration weight loss drugs deal,” nbcnews.com/health/health-news/trump-weight-loss-drugs-wegovy-zepbound-lower-price-deal-rcna241929, November 4, 2025.
U.S. Food and Drug Administration, “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize,” fda.gov, updated April 1, 2026.
GoodRx, Wegovy and Zepbound price pages, goodrx.com/wegovy and goodrx.com/zepbound, accessed September 11, 2026.
KFF, “What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge,” kff.org, updated May 11, 2026.

A stethoscope, a tape measure and scattered capsules on a white surface

Can You Do Intermittent Fasting on Ozempic or Wegovy?

On December 8, 2024September 29, 2026 By Dr. Scott RennieIn Weight Loss & Metabolic HealthLeave a comment

Weight comes up in almost every visit I do. For some patients it is fifteen pounds standing between them and a better blood pressure number. For others it is obesity that has already done damage, and the conversation starts further back. The work can feel overwhelming from the inside. What’s changed is that the tools finally match the size of the problem. Medications like Ozempic, Wegovy, Mounjaro, and Zepbound, the GLP-1 receptor agonists, have shifted how this is approached, and paired with a structure like intermittent fasting they help people lose weight and keep it off.

What GLP-1 Agonists Do

These drugs mimic glucagon-like peptide-1, a hormone that regulates appetite and blood sugar. Given as medication, they slow gastric emptying and push stronger satiety signals to the brain, so fullness arrives earlier and stays longer. They also improve insulin sensitivity, which is why they earned their place in type 2 diabetes first.

The weight effect is substantial. Wegovy and Zepbound carry FDA approval specifically for weight loss. Ozempic and Mounjaro are approved for diabetes and produce strong weight results as well, which is the source of most of the confusion patients arrive with about which drug is which.

How They Work With Intermittent Fasting

Intermittent fasting improves insulin sensitivity, supports fat loss, and helps regulate hunger hormones. Staying with it is the hard part. Many patients tell me they can’t get past the hunger. GLP-1 medications change that equation by blunting appetite and cravings, which makes a fasting schedule something a person can actually hold.

A patient of mine started a 16:8 fasting plan (16 hours fasting, 8 hours eating) while on a GLP-1 medication. Before starting the medication, she felt shaky and irritable during fasting. After starting, she was surprised by how manageable it felt. She ate smaller meals, felt full, and didn’t struggle to maintain the fasting window.

Side Effects and Adjustments

Nausea leads the list, and it’s worst early. Diarrhea and reflux show up too. Most of it settles as the body adapts. Start low, titrate slowly, and resist the urge to chase the next dose because the scale stalled for two weeks. Patients who stay in contact through the titration get their dose adjusted before they quit over side effects, and the ones who go quiet are the ones who stop the drug entirely.

Barriers to Access

Getting these medications is its own project. Cost is the main wall. Insurance coverage for weight loss remains inconsistent in a way that’s hard to explain to a patient who has just been told the drug would help, and out-of-pocket pricing is punishing. Demand has outrun supply, so delays and shortages are part of the picture.

Then there are the compounded versions. Some pharmacies sell them well below brand pricing, and they’re not FDA-approved. Safety and potency can’t be guaranteed. I tell patients to stay away from them, and I don’t soften that advice when someone pushes back on price.

Putting It Into Context

These aren’t quick fixes. They are tools, and they work when they sit on top of durable changes: balanced eating, regular activity, attention to mental health. Intermittent fasting is one workable way to structure eating alongside them. The lifestyle piece doesn’t become optional because a medication is doing part of the lifting.

When patients pair the medication with habits they can sustain, results hold longer and vary less. The goal is a set of strategies that still works three years from now, not the fastest possible drop on the scale.

Why your compounded supply is drying up

Why can’t I just convert my compounded dose?

Restart low, or match the dose?

What I would gather before the video visit

What restarting will feel like

What will the brand version cost?

Pills as a way out

Gray-market sellers and “research use” vials

If you are the patient

If you are the clinician

The Bottom Line

Related Reading

Sources

Why you want to stop matters more than the fact that you want to stop

What the evidence actually shows

It is physiology, not a character flaw

Most people stop anyway

What I actually do: lower the dose rather than stop

When the reason is cost

Protecting muscle

When I bring up the long-term question, and why not sooner

When I support stopping

Restarting

For clinicians

The Bottom Line

Related Reading

Sources

Why the two pills work so differently in your body

What the labels actually say, and why the number in your news feed is wrong

The only comparison anyone has run, and who paid for it

Birth control is the difference nobody mentions

The other interactions that quietly decide this

Side effects

If you have heart disease, the answer is already made

How I actually choose

What this costs right now

The Bottom Line

Related Reading

Sources

Why compounded versions exist

Key risks and what to look for

How I approach this with patients

The FDA’s BeSafeRx campaign

What’s changed recently

Related Reading

What Actually Changed

Wegovy: Injection and Pill, Two Different Price Ladders

Zepbound: LillyDirect’s Vial and Pen Pricing

Foundayo: The Oral Option From Lilly

Medicare, Medicaid, and the Federal Programs

Current Self-Pay Prices at a Glance

The Compounding Chapter Is Closed

For Patients

For Clinicians

The Bottom Line

Related Reading

Sources

What GLP-1 Agonists Do

How They Work With Intermittent Fasting

Side Effects and Adjustments

Barriers to Access

Putting It Into Context

Related Reading

Sources